BioMarin's Roller Coaster Continues

BioMarin Pharmaceutical's (NASDAQ: BMRN) second-quarter earnings report was a bit of a mixed bag, with some drugs growing, some on their typical roller-coaster ride, and earnings slipping due to increased spending on research and development.

While short-term investors may be a bit disappointed, long-term shareholders should look past the quarterly noise, as management reaffirmed 2019 guidance.

Metric

Continue reading

Quelle Fool.com